James L. Cox - 20 Mar 2025 Form 4 Insider Report for Adagio Medical Holdings, Inc. (ADGM)

Role: Director
Signature: /s/ John Dahldorf, Attorney-in-Fact
Issuer symbol: ADGM
Transactions as of: 20 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 21 Mar 2025, 19:00:18 UTC
Previous filing: 21 Feb 2025
Next filing: 24 Feb 2026
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADGM	Non-qualified stock option (right to buy)	Award	$0	+90,000		$0.000000	90,000	20 Mar 2025	Common Stock	90,000	$0.8650	Direct	F1
transaction	ADGM	Non-qualified stock option (right to buy)	Award	$0	+364,000		$0.000000	364,000	20 Mar 2025	Common Stock	364,000	$0.8650	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Stock option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Option will vest over a three-year period, whereby 1/36th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of July 31, 2024.
F2	Stock Option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Special Option"). Special Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Special Option is vested in full as of the grant date.

Content

Stock option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Option will vest over a three-year period, whereby 1/36th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of July 31, 2024.

Stock Option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Special Option"). Special Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Special Option is vested in full as of the grant date.